natureresearch

Corresponding author(s):	Hua Lu
Last updated by author(s):	Apr 29, 2019

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

_					
ζ	ŀ۵	ti	c	۲i	CS
J	ıа	u	ادا	u	CO

For all statistical analys	ses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.					
n/a Confirmed						
☐ ☐ The exact sam	nple size (n) for each experimental group/condition, given as a discrete number and unit of measurement					
A statement of	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly					
The statistical Only common t	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.					
A description	of all covariates tested					
A description	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
A full descript AND variation	cion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
For null hypot	thesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted is exact values whenever suitable.					
For Bayesian	analysis, information on the choice of priors and Markov chain Monte Carlo settings					
For hierarchic	cal and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
Estimates of e	effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated					
,	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and o	code					
Policy information abo	ut <u>availability of computer code</u>					
Data collection	The RNA-seq data were generated via the Illumina HiSeq sequencing platform. The clock activity data were collected by measuring the luminescence with an Omega Luminescence Reader.					
Data analysis	The analyses of RNA-seq data and the circadian clock data were achieved by using available R packages.					

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Source data are provided in the paper, its supplementary files, and a Source Data file for Figures 1B, 1D-1G, 2B-2G, 3B-3F, 4A-4D, 5B-5D, 5F-5H, 5J-L, Supplementary Figures 1, 2, 5, 6, 7, 8, and 9). The RNA-seq data are deposited in the National Center for Biotechnology Information Gene Expression Omnibus database with accession number GSE115680.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers.

Field-spe	ecific r	eporting		
Please select the or	ne below tha	t is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
X Life sciences		Behavioural & social sciences		
For a reference copy of t	:he document w	ith all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scier	nces s	tudy design		
All studies must dis	close on the	se points even when the disclosure is negative.		
Sample size	The sample s	size was chosen on the basis of prior studies that showed significant effects with similar sample sizes.		
Data exclusions	Data from co	om contaminated samples, e.g. contaminated seedlings and plates, were excluded.		
Replication	Replicated e	experiments were successful and support conclusions drawn in this report.		
Randomization	Samples wer	ere chosen randomly from each genotype per treatment per time point.		
Blinding	Investigators were not blinded during experiments.			
Poportin	a for a	specific materials, systems and methods		
		rs about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exp	perimenta	l systems Methods		
n/a Involved in th	ne study	n/a Involved in the study		
Antibodies		ChIP-seq		
Eukaryotic	cell lines	Flow cytometry		
Palaeontol	ogy	MRI-based neuroimaging		
Animals an	d other organ	isms		
Human res	earch particip	ants		
Clinical dat	a			
Antibodies				
Antibodies used		Anti-GFP antibodies (Abcam, product code 290) and whole rabbit IgG (mock) (Jackson ImmunoResearch cat 011-000-003) coated		
Alltinodies dsed		onto Dynabeads Protein G (Invitrogen cat 100.04D) were purchased from indicated manufacturers.		

known LUX gene promoter targets, including the LBS sites in PRR7, PRR9, and GI promoters.

The effectiveness of the antibodies was confirmed by the ChIP experiment that showed the binding of the LUX protein to several

Validation